Pfizer’s new crown oral drug reduces the risk of hospitalized death by 89%, but further research is needed to statistically determine the exact cure rate.
The ninth edition of the guidelines for the diagnosis and treatment of neocoronaviral pneumonia includes the company’s ritonavir tablets as an antiviral drug for the treatment of neocoronaviral pneumonia, and according to the FDA (U.S. Food and Drug Administration), ritonavir tablets were able to reduce the risk of hospitalization and death by 89%.
However, the specific cure rate is still unclear, on the one hand, the cause of death of patients infected with C.N.C.P. includes their own chronic diseases, age and many other factors, on the other hand, the real large-scale application of a relatively short period of time, it is still necessary to go through a large number of clinical applications and data statistics, in order to give the final cure rate.
[Tip] In this article, “new coronary pneumonia, new coronary virus pneumonia”, etc., has been December 26, 2022, the National Health Commission issued a notice to change the name to “new coronary virus infection”.